healthcare policy professional with deep insight and knowledge of the
biopharmaceutical industry, public policy and advocacy, and market access.
International experience living in Europe and Japan.
Public policy analysis Pharmaceutical consulting Strategic policy planning
Client management Technical writing Corporate and government affairs
Senior Consultant, Life Sciences, 02/2012 to Current IHS – Washington, DC Manage pharmaceutical consulting projects from lead generation, budget negotiation, and client updates to presentation of deliverables. Work includes: market assessments, policy analyses, and systemic literature reviews.
manager on engagement to analyze patient access to medicines in 7 European and
Asia-Pacific countries. Managed work of US and European team members.
health technology assessment case studies for pharmaceutical trade association.
Client used results for advocacy on key HTA practices and methods.
and supervised market access and reimbursement pre-launch assessments for
antiviral, neuroscience, oncology, and rare disease products under retainer
with top 10 biopharmaceutical company.
manager for research study on impact of statin therapy on health outcomes. Led
development of manuscript for scientific publications; poster presentation
accepted at ISPOR Latin America.
2013 annual business development sales goal by 58%. Exceeded 2013 revenue managed
goal by 6%.
Senior Manager, International Policy, 08/2006 to 12/2011 Pfizer – Collegeville, PA Responsible for legislative and regulatory analyses and monitoring competitive activity in biopharmaceutical sector.
policy position papers on innovation, intellectual property, biosimilars, and
counterfeiting in collaboration with Public Affairs, Government Affairs, and
Business Unit colleagues.
meeting with Japanese official to discuss strategies for enhancing access to
pediatric and adult vaccinations in Japan.
cross-functional task force that developed company-wide response to National
Institute of Health's request for comments on clinical trial registry reporting
Pfizer to external organizations and officials, including PhRMA and BIO.
Editor, 01/2000 to 01/2005 "The Pink Sheet" – Rockville, MD Managed online and print news service providing healthcare industry coverage to pharmaceutical company executives, investment analysts, consultants, and policymakers.
3-5 articles per week on Capitol Hill, regulatory, legal, and business issues.
and followed up on news leads and with contacts to develop story ideas and
Research Assistant, 09/1996 to 12/1999 American Enterprise Institute – Washington, DC Assisted health economist with data collection, book research, and conference planning at leading think tank.
credits in two AEI Press books: Prices, Markets, and the Pharmaceutical
Revolution (2000) and Fear of Persuasion (1997).
MBA: International Business, Temple University - Philadelphia, PA Program included residences in Paris, France and Tokyo, Japan.
Bachelor of Arts: Psychology, Harvard University - Cambridge, MA
Secretary for non-profit, non-partisan organization that hosts debates on current
political, policy, and social issues.
Council on Foreign Relations
Awarded 2009-2010 fellowship to study at the Research Institute of
Economy, Trade, and Industry (RIETI) in Tokyo.
Researched Japan's life
sciences strategy through interviews with government, academic, and industry officials.
TM, Blanchard TD, Gallo PD, and
Semilla AP. The economic impact of Medicare Part D on congestive heart failure.
Am J Manag Care 2013;19:S97-S100.
SL, Storm MV, Semilla AP, and Blanchard
TD. Estimating the impact of statin therapy across developed and emerging
markets: case studies in Mexico and Sweden. (forthcoming)